Evaluating PET/CT for diagnosing Tau-related diseases
Beta Amyloid PET/CT in Various Aβ-Related Disease
Tianjin Medical University · NCT06725706
This study is testing if a special type of brain scan can help doctors better diagnose Tau-related diseases in adults with suspected or newly diagnosed tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tianjin Medical University (other) |
| Locations | 3 sites (Hefei, Anhui and 2 other locations) |
| Trial ID | NCT06725706 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness of 18F-92/AV45 and 11C-PIB positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with various Tau-related diseases. Participants, who are adults with suspected or newly diagnosed malignant tumors, will undergo PET/CT scans to quantify lesion uptake using the maximum standard uptake value (SUVmax). The study will calculate key diagnostic metrics such as sensitivity, specificity, and accuracy to determine the utility of these imaging techniques.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with suspected or newly diagnosed malignant tumors requiring Aβ PET/CT scans.
Not a fit: Patients with non-malignant lesions or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance diagnostic accuracy for patients with Tau-related diseases, leading to better treatment decisions.
How similar studies have performed: Previous studies have shown promise in using PET imaging for similar diagnostic purposes, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Aβ PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Hefei, Anhui and 2 other locations
- The First Affiliated Hospital of University of Science and Technology of China — Hefei, Anhui, China (RECRUITING)
- Chinese PLA General Hospital, — Beijing, Beijing Municipality, China (RECRUITING)
- Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Ying Wang, MD
- Email: macrossplusvoices@163.com
- Phone: +8618702292537
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Amyloid, Beta-Amyloid, Neurodegenerative Diseases, PET/CT, MRI